DexCom, Inc. (DXCM) reported first-quarter 2024 adjusted earnings per share (EPS) of 32 cents, which beat the Zacks Consensus Estimate of 27 cents by 18.5%. The company reported earnings of 17 cents per share in the prior-year quarter.DXCM registered GAAP net income per share of 36 cents, up from the year-ago quarter’s figure of 12 cents.Revenue DetailsTotal revenues grew 24% (25% on an organic basis) to $921 million on a year-over-year basis and beat the Zacks Consensus Estimate by 1.1%. Strong revenue gro ...

DexCom, Inc. (NASDAQ:DXCM) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Danielle Antalffy - UBS Securities Robbie Marcus - J.P. Morgan Larry Biegelsen - Wells Fargo Joanne Wuensch - Citibank Jeff Johnson - Robert W. Baird Jason Bedford - Raymond James Malgaret Andrew - Willi ...

For the quarter ended March 2024, DexCom (DXCM) reported revenue of $921 million, up 24.2% over the same period last year. EPS came in at $0.32, compared to $0.17 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $911.2 million, representing a surprise of +1.08%. The company delivered an EPS surprise of +18.52%, with the consensus EPS estimate being $0.27.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEXCOM, INC. (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdiction ...

• • • • Three Months Ended March 31, Three Months Ended March 31, (In millions) 2024 2023 (In millions, except per share data) 2024 2023 GAAP gross profit $ 561.9 $ 462.6 GAAP net income $ 146.4 $ 48.6 Amortization of intangible assets (1) 7.2 7.2 Amortization of intangible assets (1) 10.4 9.0 Non-GAAP gross profit $ 569.1 $ 469.8 Business transition and related costs (2) 3.5 1.1 Intellectual property litigation costs (3) 25.2 21.3 GAAP operating income $ 101.1 $ 47.2 Adjustments related to taxes (4) (57.3) ...

Exhibit 99.1 Dexcom Reports First Quarter 2024 Financial Results SAN DIEGO - (BUSINESS WIRE-April 25, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: • Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. • U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an organic1 basis, ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about DexCom (DXCM) .DexCom currently has an average brokerage recommen ...

Wall Street analysts forecast that DexCom (DXCM) will report quarterly earnings of $0.27 per share in its upcoming release, pointing to a year-over-year increase of 58.8%. It is anticipated that revenues will amount to $911.2 million, exhibiting an increase of 22.9% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projec ...

The Medical Instruments industry is once again in a transformative phase. With the pandemic-led crisis over now, the industry is now seeing rapid adoption of generative Artificial Intelligence (genAI) and digital therapeutics, which, according to market watchers, is expected to take the healthcare industry by storm.In fact, since the beginning of 2023, the industry has been witnessing the adoption of AI and the Internet of Medical Things in the form of digital healthcare options in hospitals and other healt ...

DexCom Inc. (DXCM) and MD Revolution recently announced their partnership, where Dexcom is likely to integrate its industry-leading continuous glucose monitoring (CGM) systems with MD Revolution’s remote care management.Dexcom’s wearable devices pair with users' smartphones to monitor glucose levels. As a result of the partnership, patients' glucose monitoring data can now be made available to clinicians through MD Revolution’s care management platform, which is likely to empower clinicians to make informed ...